Plain-English translation of NCT07218380 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a new medication called to see if it works better than a placebo (inactive pill) when combined with two other cancer-fighting drugs: enfortumab vedotin and . The trial focuses on people with advanced bladder cancer that has a particular genetic change called an FGFR3 alteration, which this medication is designed to target. Researchers want to learn whether adding this treatment helps patients live longer and controls their cancer better.
Advanced bladder cancer is very serious, and current treatment options are limited, especially for patients who haven't received prior treatment. This medication targets a specific genetic change found in some bladder cancers, and early research suggests it may work better when combined with other proven cancer drugs.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will take the medication (or placebo) by mouth daily while also receiving two other cancer drugs through IV infusions on a set schedule. You'll have regular visits with the study team for blood tests, imaging scans, and check-ups to monitor how the treatment is working and how you're feeling. The entire study could last up to about 6 years, though your active treatment phase may be shorter depending on how your cancer responds.
AI-generated summary from trial data · Aug 19, 2026 · Not medical advice
United States